Skip to main content

Day: December 11, 2021

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

Written by Customer Service on . Posted in Public Companies.

Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable safety profile with cytokine release syndrome (all Grade 1 or 2) observed in 9 of 37 patients (24%) Patient enrollment and dose escalation is ongoing to define the RP2D and MTD Management to host webcast and conference call to review the HPN217 data presented at ASH and provide a pipeline update on Monday, December 13, 2021 at time 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2...

Continue reading

Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab

Written by Customer Service on . Posted in Public Companies.

Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with follicular lymphoma who have received two or more prior therapies1 New efficacy data from Roche’s portfolio of cancer immunotherapies demonstrate potential of bispecific antibodies to expand upon current treatment options across several blood cancersBasel, 11 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on its CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, will be presented for the first time at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. Emerging data continue to show the promising benefit-risk profile of mosunetuzumab in relapsed or refractory (R/R) follicular lymphoma (FL), a slow-growing,...

Continue reading

The Supervisory Board renewed the authority of Sergei Bogatenkov as the Chairman of the Management Board of Admiral Markets AS

Written by Customer Service on . Posted in Public Companies.

The Supervisory Board of Admiral Markets AS decided to extend the term of office of Sergei Bogatenkov as the Chairman of the Management Board of Admiral Markets AS. His current mandate has been valid until December 18, 2021, now the term of office is extended for three years, valid until December 19, 2024. Further information:  Kaia Gil Communication Manager of Admiral Markets AS kaia.gil@admiralmarkets.com +372 53 413 764    

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.